S
ELTX icon

SignatureFD’s Elicio Therapeutics ELTX Stock Holding History

SignatureFD’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-6
Closed -$1K – 3146
2021
Q3 		$1K Buy
+6
New +$648 ﹤0.01% 2811

Other funds holding ELTX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
LSAG
Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SignatureFD's ELTX Position: Q4 2021 in Review

SignatureFD sold out of Elicio Therapeutics (ELTX) in Q4 2021, closing a stake of 6 shares — an estimated $1K sold.

SignatureFD first reported a position in ELTX in Q3 2021 and held it in 1 quarter. The position peaked at $1K in Q3 2021. 53 funds tracked by Wall St. Rank hold ELTX as of Q4 2021.

  • SignatureFD reported no remaining Elicio Therapeutics position as of Q4 2021 after selling out during the quarter.
  • SignatureFD sold 6 Elicio Therapeutics shares in Q4 2021, an estimated $1K.
  • SignatureFD first reported a position in Elicio Therapeutics in Q3 2021 and held it in 1 quarter.
  • SignatureFD's Elicio Therapeutics position peaked at $1K in Q3 2021.
  • 53 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q4 2021.

Based on SignatureFD's 13F filing for Q4 2021, filed 25 Jan 2022.